The FDA has approved Vertex’s suzetrigine, an oral inhibitor of the ion channel NaV1.8, for the treatment of moderate to severe acute pain, providing a much-needed new option. Read more about the history of the drug here tinyurl.com/5x7zyduj
The FDA has approved Vertex’s suzetrigine, an oral inhibitor of the ion channel NaV1.8, for the treatment of moderate to severe acute pain, providing a much-needed new option. Read more about the history of the drug here tinyurl.com/5x7zyduj
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
With a team of 241 researchers, we surveyed 71,922 people in 68 countries, providing the largest dataset on trust in scientists post-pandemic 👇🧵https://www.nature.com/articles/s41562-024-02090-5
With a team of 241 researchers, we surveyed 71,922 people in 68 countries, providing the largest dataset on trust in scientists post-pandemic 👇🧵https://www.nature.com/articles/s41562-024-02090-5
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
My piece in Annual Review of Biophysics on chromatin replication is now available online.
doi.org/10.1146/annu...
If you have paywall issues, try this link:
madhanilab.ucsf.edu/s/annurev-bi...
My piece in Annual Review of Biophysics on chromatin replication is now available online.
doi.org/10.1146/annu...
If you have paywall issues, try this link:
madhanilab.ucsf.edu/s/annurev-bi...
In this work, superstar postdoc @xinhexue.bsky.social combined 2 kinds of pooled CRISPR screens to pinpoint noncoding regulatory elements and the transcription factors that activate these elements.
In this work, superstar postdoc @xinhexue.bsky.social combined 2 kinds of pooled CRISPR screens to pinpoint noncoding regulatory elements and the transcription factors that activate these elements.
Abstract deadline in January!
s.embl.org/ees25-01 @EMBO/@embl.org
Abstract deadline in January!
s.embl.org/ees25-01 @EMBO/@embl.org